{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=2",
    "query": {
      "intervention": "Alemtuzumab (Campath )",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 279,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alemtuzumab+%28Campath+%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T22:46:22.679Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00331162",
      "title": "Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 222,
      "start_date": "2005-02",
      "completion_date": "2011-11-28",
      "has_results": true,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00331162"
    },
    {
      "nct_id": "NCT00315627",
      "title": "Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Islet transplantation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rodolfo Alejandro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2005-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-25",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00315627"
    },
    {
      "nct_id": "NCT01182675",
      "title": "Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Transplant Conditioning with Mobilization Only",
          "type": "DRUG"
        },
        {
          "name": "Transplant Conditioning with Mobilization and Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "Up to 3 Years"
      },
      "enrollment_count": 7,
      "start_date": "2010-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182675"
    },
    {
      "nct_id": "NCT00943319",
      "title": "Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-03",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943319"
    },
    {
      "nct_id": "NCT01935128",
      "title": "Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Arm 1 Everolimus/Reduced dose tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Toledo Health Science Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-07-03",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Toledo, Ohio",
      "locations": [
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01935128"
    },
    {
      "nct_id": "NCT03128996",
      "title": "Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Sickle Cell Disease",
        "Bone Marrow Failure Syndromes",
        "Metabolic Disorders",
        "Immunologic Disorders",
        "Hemoglobinopathies",
        "Non-malignant Disorders"
      ],
      "interventions": [
        {
          "name": "RIC regimen",
          "type": "DRUG"
        },
        {
          "name": "GVHD prophylaxis regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Day to 21 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-03-20",
      "completion_date": "2033-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03128996"
    },
    {
      "nct_id": "NCT01043640",
      "title": "Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis",
        "Hurler Syndrome",
        "Hunter Syndrome",
        "Maroteaux-Lamy Syndrome",
        "Sly Syndrome",
        "Alpha Mannosidosis",
        "Fucosidosis",
        "Aspartylglucosaminuria",
        "Adrenoleukodystrophy (ALD)",
        "Krabbe Disease",
        "Metachromatic Leukodystrophy (MLD)",
        "Sphingolipidoses",
        "Peroxisomal Disorders"
      ],
      "interventions": [
        {
          "name": "Campath-1H",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine A",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 46,
      "start_date": "2009-12",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01043640"
    },
    {
      "nct_id": "NCT00416884",
      "title": "Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "RADIATION"
        },
        {
          "name": "T-Cell Deplete",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "4 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2003-05",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2017-09-27",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00416884"
    },
    {
      "nct_id": "NCT00074282",
      "title": "Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2005-04-14",
      "completion_date": "2018-05-06",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 143,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074282"
    },
    {
      "nct_id": "NCT03784898",
      "title": "Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood draw for future biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2019-02-08",
      "completion_date": "2019-12-11",
      "has_results": true,
      "last_update_posted_date": "2022-03-28",
      "last_synced_at": "2026-10-05T22:46:22.679Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03784898"
    }
  ]
}